New clues into how the immune system remembers a dengue infection may lead to a better vaccine.
Antiviral strategies against COVID-19 broadly fall into two groups: those that target the virus and those that target the host factors that are essential for virus replication.
Tipped off by artificial intelligence, a research team is testing whether a rheumatoid arthritis drug could be repurposed as a COVID-19 treatment.
Researchers at A*STAR have uncovered a new role for a subset of immune cells in HIV infection and transmission.
Targeted mutagenesis is being used to create live-attenuated vaccines against the chikungunya virus.
A*STAR researchers have identified four peptide sequences that distinguish the Zika virus from other flaviviruses, with implications for diagnostics and vaccine development.
The antiviral protein Viperin keeps immune cells in check to prevent joint swelling during chikungunya virus infection.
A deadly bacterium uses cellular proteins as bait to sabotage a pathway that enables immune response
A joint research center at the A*STAR Institute of Bioengineering and Nanotechnology aims to improve infectious disease diagnostics
The infection of one dengue virus subtype can lead to the production of antibodies that confer protection against other dengue virus subtypes
An innovative system for detecting and identifying the viruses responsible for infectious disease should facilitate decentralized screening of suspect cases